Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28662764 | 0.87 | MAPT (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL27848741 | 0.87 | MAPT (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL12017252 | 0.76 | RAB9A (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL28688006 | 0.75 | RAB9A (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL28703889 | 0.75 | RAB9A (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL14498459 | 0.75 | MAPT (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL28688009 | 0.75 | RAB9A (0.38) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL394878 | 0.74 | P2RY1 (0.37) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL29041263 | 0.72 | TSHR (0.40) | NPC1MAPTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL30537924 | 0.72 | TSHR (0.40) | NPC1MAPTRAB9ASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2055689-B1 | Method for producing an optically active nitro compound | SUMITOMO CHEMICAL CO (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7790900-B2 | Method for producing an optically active nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| EP-2055689-A1 | Method for producing an optically active nitro compound | Sumitomo Chemical Company, Limited (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-1641740-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20070037976-A1 | such as 1-amino-2-phenylpropane by reacting unsaturated nitroolefin with organosilicon compounds such as poly(methylhydrosiloxane) and phenylsilane, in presence of asymmetric copper complex having phosphine ligand | SUMITOMO CHEMICAL COMPANY, LIMITED ERICK M. CARREIRA | 2007-02-15 | — | — | US | disclosed |
| EP-1641740-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004103951-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037976-A1 | such as 1-amino-2-phenylpropane by reacting unsaturated nitroolefin with organosilicon compounds such as poly(methylhydrosiloxane) and phenylsilane, in presence of asymmetric copper complex having phosphine ligand | L1CAM, SPATS2L, AAAS | NPC1 2046/4885MAPT 365/4885RAB9A 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.